FR10C0025I1 - - Google Patents

Info

Publication number
FR10C0025I1
FR10C0025I1 FR10C0025C FR10C0025I1 FR 10C0025 I1 FR10C0025 I1 FR 10C0025I1 FR 10C0025 C FR10C0025 C FR 10C0025C FR 10C0025 I1 FR10C0025 I1 FR 10C0025I1
Authority
FR
France
Prior art keywords
fusion polypeptides
provides
traps
interleukin
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR10C0025I1 publication Critical patent/FR10C0025I1/fr
Application granted granted Critical
Publication of FR10C0025I2 publication Critical patent/FR10C0025I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides fusion polypeptides that bind to and traps Interleukin-4 (IL-4), thus acting as am IL-4 antagonist. It also provides nucleic acid sequences that encode the fusion polypeptides, and methods of making them and uses for them.
FR10C0025C 1998-09-25 2010-04-16 IL-1 receptor fusion proteins as antagonists and methods of use and manufacture Active FR10C0025I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10185898P 1998-09-25 1998-09-25
US09/313,942 US6472179B2 (en) 1998-09-25 1999-05-19 Receptor based antagonists and methods of making and using
EP99952942A EP1115876B1 (en) 1998-09-25 1999-09-22 Receptor based antagonists and methods of making and using

Publications (2)

Publication Number Publication Date
FR10C0025I1 true FR10C0025I1 (en) 2010-05-21
FR10C0025I2 FR10C0025I2 (en) 2011-04-01

Family

ID=26798712

Family Applications (1)

Application Number Title Priority Date Filing Date
FR10C0025C Active FR10C0025I2 (en) 1998-09-25 2010-04-16 IL-1 receptor fusion proteins as antagonists and methods of use and manufacture

Country Status (19)

Country Link
US (2) US6472179B2 (en)
EP (3) EP1115876B1 (en)
JP (1) JP3902728B2 (en)
CN (1) CN100345970C (en)
AT (2) ATE283365T1 (en)
AU (1) AU758970C (en)
BE (1) BE2010C021I2 (en)
CA (1) CA2345109C (en)
DE (3) DE69922269T2 (en)
DK (1) DK1229047T3 (en)
ES (2) ES2233733T3 (en)
FR (1) FR10C0025I2 (en)
HK (2) HK1035377A1 (en)
IL (2) IL142103A0 (en)
NO (2) NO329976B1 (en)
NZ (1) NZ510720A (en)
PL (1) PL201246B1 (en)
PT (1) PT1229047E (en)
WO (1) WO2000018932A2 (en)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
IL137178A0 (en) * 1998-01-23 2001-07-24 Immunex Corp Il-18 receptors
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US7083949B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
EP1283851B1 (en) 2000-05-26 2012-03-28 Immunex Corporation Use of il-4r antibodies and compositions thereof
EP1290170A2 (en) 2000-06-16 2003-03-12 Asterion Limited Binding agents: chimeric ligand/receptor proteins
AU2001290524A1 (en) 2000-08-08 2002-02-18 Zymogenetics Inc. Soluble zcytor 11 cytokine receptors
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050112616A1 (en) * 2001-12-10 2005-05-26 William Lee Functionalized materials and libraries thereof
US7795213B2 (en) * 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US6846520B2 (en) * 2002-01-17 2005-01-25 Canon Kabushiki Kaisha Epoxy resin composition, surface treatment method, liquid-jet recording head and liquid-jet recording apparatus
AU2003243189B2 (en) * 2002-05-01 2008-01-24 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat HIV infection and AIDS
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
JP4966497B2 (en) 2002-11-15 2012-07-04 ゲンマブ エー／エス Human monoclonal antibody against CD25
US6919012B1 (en) 2003-03-25 2005-07-19 Olimex Group, Inc. Method of making a composite article comprising a ceramic coating
US8007813B2 (en) 2003-03-26 2011-08-30 Apogenix Gmbh CD95-Fc fusion proteins
US20040224893A1 (en) * 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
WO2004098596A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and il-1 trap
JP2007530009A (en) * 2003-06-11 2007-11-01 ワイス Method for producing a polypeptide
SI3095793T1 (en) * 2003-07-28 2020-07-31 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
EP1668133A4 (en) * 2003-09-05 2007-08-29 Ca Nat Research Council Coiled-coil fusion proteins comprising cell receptor domains
UA93653C2 (en) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Antibody that specifically binds to human interleukin-4 receptor (il-4r)
DE602005006758D1 (en) * 2004-02-27 2008-06-26 Regeneron Pharma IL-4 / IL-13-specific polypeptides and their therapeutic use
JP5022216B2 (en) 2004-06-04 2012-09-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Methods of using IL-1 antagonists for treating autoinflammatory diseases
ES2426005T3 (en) 2004-07-23 2013-10-18 Acceleron Pharma Inc. ACTRII receptor polypeptides, procedures and compositions
CA2576519C (en) * 2004-08-17 2013-05-21 Regeneron Pharmaceuticals, Inc. Il-1 antagonist formulations
PT1630232E (en) * 2004-08-27 2008-10-02 Conaris Res Inst Ag Optimized nucleotide sequences encoding sgp130
US7786261B2 (en) * 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
DE602005021811D1 (en) * 2004-09-13 2010-07-22 Genzyme Corp MULTI-MORE CONSTRUCTS
RU2007117716A (en) * 2004-10-12 2008-11-20 Ампротеин Корпорейшн (Us) CHIMERIC PROTEIN
AU2005299809B2 (en) 2004-10-22 2010-12-02 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
EP1848738A1 (en) * 2005-01-25 2007-10-31 Apollo Life Sciences Limited Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes
CN102614134B (en) * 2005-03-25 2016-09-07 瑞泽恩制药公司 VEGF antagonist preparation
US7732167B2 (en) * 2005-06-17 2010-06-08 Regeneron Pharmaceuticals, Inc. Interferon-α/β binding fusion proteins and therapeutic uses thereof
US7608430B2 (en) * 2005-07-08 2009-10-27 Regeneron Pharmaceuticals, Inc. Interferon-γ antagonists and therapeutic uses thereof
NI200800032A (en) 2005-07-25 2009-03-23 REDUCTION OF CELL B USING SPECIFIC JOINT MOLECULES CD37 AND CD20
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US7889347B2 (en) 2005-11-21 2011-02-15 Plexera Llc Surface plasmon resonance spectrometer with an actuator driven angle scanning mechanism
AU2006318449B2 (en) * 2005-11-23 2012-07-05 Acceleron Pharma Inc. Activin-actRIIa antagonists and uses for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US7463358B2 (en) 2005-12-06 2008-12-09 Lumera Corporation Highly stable surface plasmon resonance plates, microarrays, and methods
ES2395969T3 (en) 2006-03-24 2013-02-18 Merck Patent Gmbh Genetically modified heterodimeric protein domains
MX2008015524A (en) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Single-chain multivalent binding proteins with effector function.
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
EP1873166B1 (en) 2006-06-30 2010-09-08 CONARIS research institute AG Improved sgp 130Fc dimers
WO2008014426A2 (en) * 2006-07-28 2008-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
US8106004B2 (en) * 2006-07-28 2012-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
US7632490B2 (en) * 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
DK2124997T3 (en) * 2006-10-20 2012-08-27 Regeneron Pharma Use of IL-1 antagonists in the treatment of gout and pseudo-gout
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2008093756A1 (en) * 2007-01-30 2008-08-07 Niigata University Biological preparation
CA2677007A1 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI782836B (en) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 Variants derived from actriib and uses therefor
TWI667038B (en) 2007-02-09 2019-08-01 美商艾瑟勒朗法瑪公司 Pharmaceutical composition comprising an actriia-fc fusion protein; use of an actriia-fc fusion protein for treatment or prevention of cancer-related bone loss; use of an actriia-fc fusion protein for the treatment or prevention of multiple myeloma
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TWI573802B (en) 2007-03-06 2017-03-11 安美基公司 Variant activin receptor polypeptides and uses thereof
EP2578684B1 (en) * 2007-03-19 2016-02-24 National Research Council Of Canada Antagonists of ligands and uses thereof
WO2009010539A2 (en) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) from macaca fascicularis
US7960343B2 (en) 2007-09-18 2011-06-14 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
CA2704038A1 (en) * 2007-10-31 2009-05-07 The Scripps Research Institute Combination therapy to treat persistent viral infections
US8004669B1 (en) 2007-12-18 2011-08-23 Plexera Llc SPR apparatus with a high performance fluid delivery system
WO2010031168A1 (en) * 2008-09-17 2010-03-25 National Research Council Of Canada HETERO-MULTIVALENT BINDING AGENTS FOR MEMBERS OF THE TGFβ SUPERFAMILY
SI2132228T1 (en) 2008-04-11 2011-10-28 Emergent Product Dev Seatle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
SI3750552T1 (en) 2008-08-14 2023-10-30 Acceleron Pharma Inc. Gdf traps
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
MA32936B1 (en) 2008-11-26 2012-01-02 Amgen Inc Polypeptides of stable receptors and their uses
EP3845239A1 (en) 2009-06-08 2021-07-07 Acceleron Pharma Inc. Use of anti-actriib proteins for increasing thermogenic adipocytes
CN107267520A (en) 2009-06-12 2017-10-20 阿塞勒隆制药公司 The ACTRIIB FC fusion proteins of truncation
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
CN103298832A (en) 2010-11-08 2013-09-11 阿塞勒隆制药公司 ACTRIIA binding agents and uses thereof
EP2697260A1 (en) 2011-04-15 2014-02-19 Merck Patent GmbH Anti- il-1r1 inhibitors for use in cancer
JO3283B1 (en) 2011-04-26 2018-09-16 Sanofi Sa Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
CA2859504A1 (en) 2011-12-19 2013-07-18 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
CA2890217C (en) 2012-11-02 2021-07-20 Yifu FANG Activin-actrii antagonists and uses for treating bone and other disorders
WO2014090800A1 (en) * 2012-12-10 2014-06-19 Vib Vzw Novel interleukin-33 inhibitors
SG11201505960VA (en) 2013-02-01 2015-08-28 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject
AU2013378122B2 (en) 2013-02-15 2019-05-02 R-Pharm International, Limited Liability Company IL-1beta inhibitor composition and use thereof
WO2015192111A1 (en) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
PL3170005T3 (en) 2014-07-18 2019-10-31 Sanofi Sa Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
MA41052A (en) 2014-10-09 2017-08-15 Celgene Corp TREATMENT OF CARDIOVASCULAR DISEASE USING ACTRII LIGAND TRAPS
JP6775513B2 (en) 2014-12-01 2020-10-28 フェリング・ベー・フェー Administration of selective IL-6-trans-signal transduction inhibitors
MA41116A (en) 2014-12-01 2017-10-10 Ferring Bv SELECTIVE IL-6 TRANS-SIGNALING INHIBITOR COMPOSITIONS
BR112017011722A2 (en) 2014-12-03 2018-02-27 Acceleron Pharma Inc activin-actrii antagonists and uses for treating anemia
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
KR20190128618A (en) 2016-09-27 2019-11-18 에피센트알엑스, 인코포레이티드 Immunomodulatory fusion proteins
MX2019012570A (en) 2017-04-21 2019-12-02 Kindred Biosciences Inc Il4/il13 receptor molecule for veterinary use.
SG11202002826VA (en) 2017-09-27 2020-04-29 Epicentrx Inc Immunomodulatory fusion proteins
WO2019173692A2 (en) 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
MX2021000644A (en) 2018-07-18 2021-08-19 Manzanita Pharmaceuticals Inc Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof.
CN110950965B (en) * 2018-09-26 2021-10-15 重庆精准生物技术有限公司 Chimeric antigen receptor of anti-human CD123 and application thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
AU651596B2 (en) * 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
ATE309376T1 (en) * 1990-06-28 2005-11-15 Hoechst Ag FUSION PROTEINS WITH IMMUNGLOBULIN COMPONENTS, THEIR PRODUCTION AND USE
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
JP3122139B2 (en) * 1991-10-15 2001-01-09 マラーキー，ミッシェル，エフ． Composition for treating late stage inflammatory response
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
CA2131719C (en) * 1992-03-09 2003-09-16 Jean-Christophe Renauld Nucleic acid sequences coding for or complementary to nucleic acid sequences coding for interleukin 9 receptor
WO1993019163A1 (en) * 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
US8211422B2 (en) * 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
WO1993019777A1 (en) * 1992-03-30 1993-10-14 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
JP3255699B2 (en) 1992-04-23 2002-02-12 味の素株式会社 Human IL-2 receptor gamma chain molecule
AU695869B2 (en) * 1993-04-06 1998-08-27 Fred Hutchinson Cancer Research Center Chimeric cytokine receptors in lymphocytes
WO1995006737A1 (en) * 1993-09-03 1995-03-09 Kenneth Francis Prendergast Glycophorin binding protein (gbp130) fusion compositions
CA2174098C (en) * 1993-10-14 2011-01-25 Douglas A. Melton Method of inducing and maintaining neuronal cells
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
IL114825A0 (en) * 1994-08-04 1995-12-08 Regeneron Pharma Rtk/cytokine receptor chimeras
AU3830895A (en) 1994-10-07 1996-05-02 Amgen Boulder Inc. Dimeric il-4 inhibitors
US5837544A (en) * 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
US5837816A (en) * 1995-05-10 1998-11-17 Chiron Corporation Interleukin-2 receptor subunit ectodomain fusion protein comprising a leucine zipper domain
GB9526131D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US5776731A (en) * 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
WO1998002558A2 (en) * 1996-07-17 1998-01-22 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
WO1998008969A1 (en) * 1996-08-26 1998-03-05 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
IL137178A0 (en) * 1998-01-23 2001-07-24 Immunex Corp Il-18 receptors

Also Published As

Publication number Publication date
EP1115876B1 (en) 2006-08-16
CA2345109C (en) 2012-12-18
JP2002525119A (en) 2002-08-13
FR10C0025I2 (en) 2011-04-01
AU758970B2 (en) 2003-04-03
DE122010000023I2 (en) 2012-04-26
DE69932832D1 (en) 2006-09-28
JP3902728B2 (en) 2007-04-11
HK1045847A1 (en) 2002-12-13
CA2345109A1 (en) 2000-04-06
DE69922269D1 (en) 2004-12-30
PT1229047E (en) 2005-03-31
EP1115876A2 (en) 2001-07-18
US6472179B2 (en) 2002-10-29
BE2010C021I2 (en) 2018-12-04
US20020164690A1 (en) 2002-11-07
CN100345970C (en) 2007-10-31
DE69932832T2 (en) 2007-02-08
EP1405915A1 (en) 2004-04-07
EP1229047A3 (en) 2002-10-02
WO2000018932A9 (en) 2000-08-31
IL142103A0 (en) 2002-03-10
IL142103A (en) 2007-07-04
ES2267300T3 (en) 2007-03-01
DK1229047T3 (en) 2005-02-21
EP1229047B1 (en) 2004-11-24
NO2011003I2 (en) 2011-04-11
NO20011513D0 (en) 2001-03-23
PL201246B1 (en) 2009-03-31
NZ510720A (en) 2003-11-28
ATE283365T1 (en) 2004-12-15
US20020012962A1 (en) 2002-01-31
NO2011003I1 (en) 2011-05-02
HK1045847B (en) 2005-03-24
DE69922269T2 (en) 2005-12-01
PL348529A1 (en) 2002-06-03
NO20011513L (en) 2001-05-25
WO2000018932A3 (en) 2000-11-02
CN1357049A (en) 2002-07-03
EP1229047A2 (en) 2002-08-07
DE122010000023I1 (en) 2012-04-26
AU6499499A (en) 2000-04-17
ES2233733T3 (en) 2005-06-16
AU758970C (en) 2007-05-03
NO329976B1 (en) 2011-01-31
HK1035377A1 (en) 2001-11-23
WO2000018932A2 (en) 2000-04-06
ATE336583T1 (en) 2006-09-15

Similar Documents

Publication Publication Date Title
NO2011003I2 (en)
DE69833670D1 (en) HOMOLOGOUS OF TIE RECEPTORTYROSINE KINASE LIGANDEN
WO1996034107A3 (en) Antiviral proteins, dna coding sequences therefor, and uses thereof
PT1015585E (en) HOMES OF TIE LIGANDOS
HK1080511A1 (en) Il-1 receptor based antagonists and methods of making and using
DE69942459D1 (en) ISOLATED NUCLEIC ACID MOLECULES COPYING T CELLS INDUCIBLE FACTORS (TIF), ENCODING PROTEINS AND THEIR USE
DE69841176D1 (en) Rtd receptor
EA200400392A1 (en) BINDING KASPAZU-8 PROTEIN, ITS OBTAINING AND APPLICATION
PE20399A1 (en) MUTEINA OB
NZ512332A (en) Potassium channel interactors and uses therefor
WO2004007536A3 (en) Interactions of the epstein-barr virus protein ebna1, and uses thereof
DK0938555T3 (en) Structures and complexes of cyclin E
DK1064389T3 (en) Compositions with Fusion Proteins of Kinase Wee1, Nucleotide Sequences, Expression Systems and Methods for Their Use
SE0101700D0 (en) Nucleotide sequences